乳腺癌
免疫组织化学
医学
雌激素受体
内科学
肿瘤科
队列
癌症
转录组
雌激素受体α
生物
基因表达
病理
基因
遗传学
作者
Shorouk Makhlouf,Cecily Quinn,Michael S. Toss,Mansour Alsaleem,Nehal M Atallah,Asmaa Ibrahim,Catrin S. Rutland,Nigel P. Mongan,Emad A. Rakha
标识
DOI:10.1016/j.ejca.2023.113473
摘要
BackgroundOestrogen receptor (ER) positive breast cancer (BC) patients are eligible for endocrine therapy (ET), regardless of ER immunohistochemical expression level. There is a wide spectrum of ER expression and the response to ET is not uniform. This study aimed to assess the clinical and molecular consequences of ER heterogeneity with respect to ET-response.MethodsER expression, categorised by percentage and staining intensity in a large BC cohort (n=7,559) was correlated with clinicopathological parameters and patient ET response. The Cancer Genome Atlas Data BC cohort (n=1,047) was stratified by ER expression and transcriptomic analysis completed to better understand the molecular basis of ER heterogeneity.ResultsThe quantitative proportional increase in ER expression was positively associated with favourable prognostic parameters. Tumours with 1-9% ER expression were characteristically similar to ER-negative (<1%) tumours. Maximum ET-response was observed in tumours with 100% ER expression, with responses significantly different to tumours exhibiting ER at <100% and significantly decreased survival rates were observed in tumours with 50% and 10% of ER expression. The Histochemical-score (H-score), which considers both staining intensity and percentage, added significant prognostic value over ER percentage alone with significant outcome differences observed at H-scores of 30, 100 and 200. There was a positive correlation between ER expression and ESR1 mRNA expression and expression of ER-regulated genes. Pathway analysis identified differential expression in key cancer-related pathways in different ER-positive groups.ConclusionET-response is statistically proportionally related to ER expression with significant differences observed at 10%, 50% and 100%. The H-score adds prognostic and predictive information.
科研通智能强力驱动
Strongly Powered by AbleSci AI